Challenge: ENTEREG was the first FDA approved therapy for post-operative ileus an uncomfortable side effect of gastrointestinal surgery that can prolong hospital stay by one to three days. ENTEREG is costly and also has a mandated REMS (Risk Evaluation and Mitigation Strategy) which requires additional clinical oversight

Strategic Approach: Develop a short and concise pharmacoeconomic primer to assist P&T committees understand the how the cost of drug acquisition cost and additional clinical oversight is outweighed in most patients by significantly shorter hospital stays leading to overall lower healthcare utilization costs